Loading company…
MEPSGEN develops platforms and instruments for pharmaceutical drug discovery and development.
MEPSGEN offers ProMEPS™, MEPS-X series and NanoCalibur™ products for drug discovery, microfluidic compound handling and drug formulation. Founded in 2020 and based in Seoul, South Korea, the company raised KRW 20.7 billion in Series C funding in November 2024 from Yuanta Investment, KB Securities, Solidus Investment, E&Investment, and Live Cell Instrument, with KDB Bank and SBI Investment Korea also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in